A guide to clinically relevant drug interactions in oncology

Journal of Oncology Pharmacy Practice

Volumn 9, Issue 2-3, 2003, Pages 45-85

  Lam, Marsha S H ^a   Ignoffo, Robert J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticancer drugs; Clinically relevant; Drug drug interactions; Oncology; Pharmacodynamic interactions; Pharmacokinetic interactions

Indexed keywords

ALEMTUZUMAB; ALTRETAMINE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; BEXAROTENE; BICALUTAMIDE; BLEOMYCIN; BLEOMYCIN SULFATE; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; UNINDEXED DRUG; WARFARIN;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOTOXICITY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GRANULOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 0041360161     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155203jp107oa     Document Type: Review

References (264)

1. Nies AS. Principles of therapeutics. In Hardman JG, Limbird LE, Goodman A editors. Goodman & Gilman's the pharmacological basis of therapeutics, tenth edition. New York: McGraw-Hill Medical Publishing, 2001: chapter 3.
2. Finley RS. Drug interactions in the oncology patient. Semin Oncol Nurs 1992; 8: 95-101.
3. Food and Drud Administration MedWatch Website. The FDA Safety Information and Adverse Event Reporting Program. Available at http:/www/fda.gov/medwatch/safety.htm (accessed 21 January 2003).
4. Shiloni E, Matzner Y. Inhibition of interleukin-2-induced tumor necrosis release by dexamethasone: does it reduce the antitumor therapeutic efficacy? Blood 1991; 78: 1389-90.
5. Piscitelli SC, Vogel S, Figg WD, Raje S, Forrest A, Metcalf JA, et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998; 18: 1212-16.
6. Chabot GC, Flaherty LE, Valdivieso M, Baker LH. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 1990; 27: 157-60.
7. Paolini A, D'Incalci M. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine. Cancer Treat Rep 1986; 70: 513-16.
8. Hande K, Combs G, Swingle R, Combs GL, Anthony L. Effect of cimetidine and ranitidine on the metabolism and toxicity of hexamethylmelamine. Cancer Treat Rep 1986; 70: 1443-45.
9. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990; 50: 5851-57.
10. Van Deijk WA, Blijham GH, Mellink WA, Meulenburg PM. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. Cancer Treat Rep 1985; 69: 85-90.
11. Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemother Pharmacol 1984; 12: 10-12.
12. Lonning PE, Ueland PM, Kvinnsland S. The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer. Cancer Chemother Pharmacol 1986; 17: 177-81.
13. Lonning PE, Kvinnsland S, Bakke OM. Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. Clin Pharmacol Ther 1984; 36: 796-802.
14. Halpern J, Catane R, Baerwald H. A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment. J Med 1984; 15: 59-63.
15. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001; 51: 429-35.
16. Capizzi RL. Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 1974; 23: 151-61.
17. Murphy JA, Ross LM, Gibson BES. Vincristine toxicity in five children with acute lymphoblastic leukaemia (letter). Lancet 1995; 346: 443.
18. Petro WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy 1992; 12: 273-77.
19. Product Information. Casodex®, bicalutamide. Zeneca Pharmaceuticals, Wilmington, DE, (PI revised 9/2000).
20. Yee GC, Crom WR, Champion JE, Brodeur GM, Evans WE. Cisplatin-induced changes in bleomycin elimination. Cancer Treat Rep 1983; 67: 587-89.
21. Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol 1984, 12: 313-17.
22. Bennett WM, Pastore L, Houghton DC. Fatal pulmonary toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980; 64: 921-24.
23. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, et al. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-24.
24. Hassan M, Oberg G, Bjorkholm M, Wallen I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulfan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-86.
25. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res 1996; 16: 2083-88.
26. Key NS, Kelly PMA, Emerson PM, Chapman RW, Allan NC, McGee JO. Oesophageal varices associated with busulfan-thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987; 2: 1050-52.
27. Product Information. Xeloda®, capecitabine. Roche Pharmaceuticals, Nutley, NJ, USA, 2001, (revised 9/2001).
28. Giaccone G, Huizing M, Postmus PE, ten Bokkel Huinink WW, Koolen M, van Zandwijk N, et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 1995; 22 (Suppl 9): 78-82.
29. Bookman MA, McGuire WP III, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-1902.
30. Kearns CM, Belani CP, Erkmen K, Zuhowski M, Hiponia D, Engstrom C, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 1995; 14: 170 (abstract).
31. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women ovarian cancer: the ICON3 randomized trial. Lancet 2002; 360: 505-15.
32. Selker RG, Moore P, Lodolce D. Bone-marrow depression with cimetidine plus carmustine (letter). N Engl J Med 1978; 299: 834.
33. Volkin RL, Shadduck RK, Winklestein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppresion by cimetidine. Arch Intern Med 1982; 142: 243-45.
34. Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989; 115: 41-46.
35. Bjornsson TD, Huang AT, Roth P, Jacob DS, Christensen R. Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. Clin Pharmacol Ther 1986; 39: 25-28.
36. Wolff SN. High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity. Cancer Treat Rep 1986, 70: 1464-65.
37. Levin VA, Stearns J, Byrd A, Finn A, Weinkam RJ. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 1979; 208: 1-6.
38. Schellens JHM, Ma J, Bruno R. Pharmacokinetics of cisplatin and taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 1994; 13: 132.
39. Pronk LC, Schellens JHM, Planting AST, van den Bent MJ, Hilkens PH, van der Burg ME et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-79.
40. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997; 75: 417-22.
41. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 2459-65.
42. Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jurgens J. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12: 159-65.
43. Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Ifosfamide neurotoxity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990; 8: 1399-1401.
44. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH. Potentiation of ifosfamide neurotoxicity, hematoxicity and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy. Cancer Res 1987; 47: 1457-60.
45. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-84.
46. Haas A, Anderson L, Lad T. The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J Infect Dis 1983; 147: 363.
47. Bergstrom P, Johnsson A, Cavallin-Stahl E, Bergenheim T, Henriksson R. Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Eur J Cancer 1997; 33: 153-59.
48. Christensen ML, Stewart CF, Crom WR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit 1989; 11: 631-36.
49. Product Information. Rituxan®m rituximab. Genentech, Inc., South San Francisco, CA, (PI revised 4/2001).
50. Komune S, Snow JB. Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Arch Otolaryngol 1981; 107: 594-97.
51. Kohn S, Fradis M, Podoshin L, David YB, Zidan J, Robinson E, Nir I. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope 1997, 107: 407-408.
52. Riggs LC, Brummett RE, Guitjens SK, Matz GJ. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1996; 106: 401-406.
53. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forasteire AA, et al. Sequences of taxol and cisplatin: a phase and pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
54. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989; 87: 505-10.
55. Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43: 372-75.
56. Dorr RT, Soble MJ, Alberts DS. Interaction of cimetidine but not ranitidine with cyclophosphomide in mice. Cancer Res 1986, 46: 1795-99.
57. Albert DS, Mason-Liddil N, Pleiza PM, Roe DJ, Dorr RT, Struck RF, Phillips JG. Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial. J Natl Cancer Inst 1991; 83: 1739-42.
58. Kennedy MJ, Zahurak Ml, Donehower RC, Noe DA, Sartorius, Chen TL, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 1996; 14: 783-91.
59. Tolcher AW, Cowan KH, Noone M, Denicoff AM, Kohler DR, Goldspiel BR, et al. Phase I study of paclitaxel in combination with cyclophophamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 1996; 14: 95-102.
60. Product Information. Herceptin®, trastutuzumab. Genentech, Inc., South San Francisco, CA, 1998.
61. Oira S, Maezawa S, Irinoda Y, Watanabe K, Kitada K. Increased antitumor activity of cyclophosphamide (Endoxan) following pretreatment with inducer of drug-metabolizing enzymes (cytochrome P-450). Tohoku J Exp Med 1974, 114: 55-60.
62. Gryn J, Gordon R, Bapat A, Goldman N, Goldberg J. Pentostatin increases the acute toxicity of high-dose cyclophosphamide. Bone Marrow Transplant 1993, 12: 217-20.
63. Varis T, Kivisto K, Backman J, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamenthasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000; 68: 487-94.
64. McLelland J, Jack W. Phenytoin/dexamethasone interaction: a clinical problem (letter). Lancet 1978; 1: 1096-97.
65. Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M. Phenytoin-dexamethasone: a possible drug-drug interaction. JAMA 1985, 254: 2062-63.
66. Privitera MR, Greden JF, Gardner RW, Richie JC, Carroll BJ. Interference by carbamazepine with the dexamethasone suppression test. Biol Psychiatry 1982; 17: 611-20.
67. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17: 1516-25.
68. Zamboni W, Egorin M, Van Echo, Day RS, Meisenberg BR, Brooks SE, et al. Pharmacokinetic and pharmaco-dynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 2000; 18: 3288-94.
69. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58-65.
70. Schuller J, Czejka M, Kletzl H, Wirth M, Springer B, Kriwanek S, et al. Doxorubicin (DOX) and Taxotere (TXT): A pharmacokinetic study of the combination in advanced breast cancer. Proc Am Soc Clin Oncol 1998; 17: 205a (abstract 790).
71. Cattel L, Recalenda V, Airoldi M, Tagini V, Arpicco S, Brusa P, Bumma C. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco. 2001; 56: 779-84.
72. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834-41.
73. Barbui T, Rambaldi A, Parenzan L, Zucchelli M, Perico N, Remuzzi G. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporine therapy. Lancet 1992; 339: 1421.
74. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 2713-21.
75. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicn and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15.
76. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, et al. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86: 143-45.
77. Chang P, Riggs CE Jr, Scheerer MT, Wiernik PH, Bachur NR. Combination chemotherapy with adriamycin and streptozotocin: Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin. Clin Pharmacol Ther 1976; 20: 611-16.
78. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, et al. Reversal of multidrug resistance by SDZ PSC833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10: 1741-50.
79. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 2001; 7: 1221-29.
80. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-15.
81. Zangari M, Anaissie E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
82. Minow RA, Stern MH, Casey JH, Rodriquez V, Luna MA. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adriamycin. Cancer 1976; 38: 1524-28.
83. Rodriguez V, Bodey GP, McCredie KB, Freireich EJ, Monow RA, Casey JH, Luna M. Combination 6-mercaptopurine-adriamycin in refractory adult acute leukemia. Clin Pharmacol Ther 1975; 18: 462-65.
84. Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol 1998, 10: 35-38.
85. Venturini M, Lunardi G, Del Mastro L, Vannozzi MO, Tolino G, Numico G, et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000, 18: 2116-25.
86. Product Information: Emcyte®, estramustine phosphate sodium. Kabi Pharmacia, Piscataway, NJ, 1999.
87. Lum B, Kaubisch S, Yahanda A, Adler KM, Jew L, Ehasn MN, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
88. Bisogno G, Cowie F, Boddy A, Thomas HD, Dick G, Pinkerton CR. High-dose cyclosporin with etoposide-toxicity and pharmacokinetic interaction in children with solid tumors. Br J Cancer 1998; 7: 2304-309.
89. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992; 10: 1624-34.
90. Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 2002; 16: 920-27.
91. Keller A, Altermatt H, Donatsch P, et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vitro cytostatic activity and toxicity. Int J Cancer 1992; 51: 433-38.
92. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, et al. Phase I study of etoposide with SDZ PSC833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-18.
93. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapses or refractory acute myelogenous leukemia. J Clin Oncol 1997; 15: 1796-1802.
94. Rodman JH, Murry DJ, Madden T, Santana VM. Pharmacokinetics of high doses of etoposide and the influence of anticonvulsants in pediatric cancer patients. Clin Pharmacol Ther 1992; 51: 156.
95. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997; 31: 1006-1008.
96. Ward K, Bitran JD. Warfarin, etoposide, and vindesine interactions. Cancer Treat Rep 1984; 68: 817-18.
97. Product Information. Fludara®, fludarabine. Berlex Laboratories, Wayne, NJ, 1997.
98. Product Information: Nipent®, pentostatin. Parke-Davis, Morris Plains, NJ, 1994.
99. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high dose folinic acid: a pilot study. Cancer Treat Rep 1982; 66: 1803-807.
100. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993; 11: 2386-90.
101. Benz C, Tillis T, Tattelman E, Cadman E. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 1982; 42: 2081-86.
102. Barkakji Z, Jolivet J, Langelier Y, Besner JG, Ayoub J. 5- Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 1986; 18: 140-44.
103. Wajima T, Mukhopadhyay P. Possible interactions between warfarin and 5-fluorouracil (letter). Am J Hematol 1992; 40: 238.
104. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994; 28: 464-67.
105. Brown MC. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 1999; 45: 392-395.
106. Aki Z, Kotiloglu G, Ozyilkan O. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin (letter). Am J Gastroenterol 2000; 95: 1093-1094.
107. Chlebowski RT, Gota CH, Chan KK, Weiner JM, Block JB, Bateman JR. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 1982; 42: 4827-30.
108. Lokich JJ, Pitman SW, Skarin AT. Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer. Oncology 1975, 32: 34-37.
109. Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 1984; 18: 421-30.
110. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95: 1629-36.
111. Product Information. Eulexin®, flutamide. Schering Corporation, Kenilworth, NJ, (PI revised 03/2001).
112. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 1999; 19: 1331-33.
113. Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 2001; 67: 223-33.
114. Longhurst HJ, Pinching AJ. Pancreatitis associated with hydroxyurea in combination with didanosine. BMJ 2001; 322: 81.
115. Hall G, Lind MJ, Huang M, Moore A, Gane A, Roberts JT, Cantwell BM. Intravenous infusions of ifosfamide mesna and perturbation of warfarin anticoagulant control. Postgrad Med J 1990; 66: 860-61.
116. Kerbusch T, Jansen RLH, Mathot RAA, Huitema AD, Jansen M, van Rijswijk RE, Beijnen JH. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 2001; 70: 132-41.
117. Product Information. Gleevec®, imatinib mesylate. Novartis Pharmaceuticals Corp. (PI revised 05/2001).
118. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-42.
119. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-37.
120. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987; 24: 939-41.
121. Product Information. Retrovir®, zidovudine. Glaxo Wellcome Inc., Research Triangle Park, NC, 1996.
122. Kehrer DFS, Mathijssen RHJ, Verweij J, de Bruijn P, Sparreboom P. Modulation of irinotecan by ketoconazole. J Clin Oncol 2002; 20: 3122-29.
123. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom P. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-49.
124. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, Blaney SM. Influence of phneytoin on the disposition of of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24: 130-33.
125. Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs. 2002; 13: 139-40.
126. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt). 2002; 16 (8 Suppl 7): 33-40.
127. Dowsett M, Pfister C, Johnston SRD, Miles DW, Houston SJ, Verbeek JA, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338-43.
128. Perez-Gallardo L, Blanco ML, Soria H, Escanero JF. Displacement of rifampicin bound to serum proteins by addition of levamisole. Biomed Pharmacother 1992; 46: 173-74.
129. Hess WA, Kornblith PL. Combination of lomustine and cimetidine in the treatment of a patient with malignant glioblastoma: a case report. Cancer Treat Rep 1985; 69: 733.
130. Muller PJ, Tator CH, Bloom ML. Use of phenobarbital and high doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the treatment of brain tumor-bearing mice. Cancer Res 1983; 43: 2068-71.
131. Sviland L, Robinson A, Proctor SJ, Bateman DN. Interaction of cimetidine with oral melphalan: a pharmacokinetic study. Cancer Chemother Pharmacol 1987; 20: 173-75.
132. Berns A, Rubenfeld S, Rymzo WT Jr. Hazard of combining allopurinol and thiopurine (letter). N Engl J Med 1972; 286: 730.
133. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34: 810-17.
134. Spiers AS, Mibashan RS. Lancet 1974, 2: 221-2.
135. Balis FM, Holcenburg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987; 41: 384-87.
136. Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 1996; 37: 409-14.
137. Schmiegelow K, Bretton-Meyer U. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia 2001, 15: 74-79.
138. Frenia ML, Long KS. Methotrexate and non-steroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26: 234-37.
139. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 121-25.
140. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986; 1: 1390.
141. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17: 1469-73.
142. Furst DE, Herman RA, Koehnke R, Ericksen N, Hash L, Riggs CE, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci. 1990; 79: 782-86.
143. Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. J Cancer Res Clin Oncol 1985; 110: 48-50.
144. Korstanje MJ, van Breda Vriesman CJP, van de Staak WJBM. Cyclosporine and methotrexate: a dangerous combination. Am Acad Dermatol 1990; 23: 320-21.
145. Cohen MH, Creaven PJ, Fossieck BE, Johnston AV, Williams CL. Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients. Cancer 1976; 38: 1556-59.
146. Liegler DG, Henderson ES, Hahn MA, Olivero VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969; 10: 849-57.
147. Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV, Pla JM. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993; 15: 375-79.
148. Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol 1992; 14: 88-92.
149. Riva R, Albani F, Baruzzi A. On the interaction between phenytoin and antineoplastic agents (letter). Ther Drug Monit 1985; 7: 123-26.
150. Aherne GW, Piall E, Mark V, Mould G, White WE. Prolongation and enhancement of serum methotrexate concentration by probenecid. Br Med J 1978; 1: 1097- 99.
151. Howell SB, Olshen RA, Rice JA. Effect of probenecid on cerebrospinal fluid methotrexate kinetics. Clin Pharmacol Ther 1979; 26: 641-46.
152. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991; 18: 609-10.
153. Price P, Thompson H, Bessell EM, Bloom HJ, Renal impairment following the combined use of high-dose methotrexate and procarbazine. Cancer Chemother Pharmacol 1988; 21: 265-67.
154. Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990; 117: 823-26.
155. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13: 440-41.
156. Groenendal H, Rampen FHJ. Methotrexate and trimethoprim-sulphanethoxazole-a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358-60.
157. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole (letter). Ann Intern Med 1989; 111: 261.
158. Maricic M, Davis M, Gall EP. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 1986; 29: 133-35.
159. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64: 363-68.
160. Varis T, Kivisto K, Neuvonen P. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000; 56: 489-93.
161. Sternholm MP, Katz FH Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. J Clin Endrocrinol Metab 1975; 41: 887-93.
162. Raderer M, Kornek G, Hejna M, Vorbeck F, Weinlaender G, Scheithauer W. Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol 1996; 7: 973-75.
163. Rivera MP, Kris MG, Gralla RJ, White DA. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol 1995; 15: 245-50.
164. Rao SX, Ramaswamy G, Levin M, McGravey JW. Fatal Acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985; 145: 1905-907.
165. Hoelzer KL, Harrison BR, Luedke SW, Luedke W. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell Clin Pharm 1986; 20: 287-89.
166. Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J, Treleaven J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993; 29A: 1854-57.
167. Product Information. Nilandron®, nilutamide. Hoechst Marion Roussel, Inc., Kansas City, MO, 1996.
168. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, Piantadosi S. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997; 15: 3121-28.
169. Kand MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 2001; 7: 1610-17.
170. Mulatero C, McClaren BR, Mason M, Loiver RT, Gallagher CJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Br J Cancer 2000; 83: 1612-16.
171. Product Information, Photofrin®, porfimer. QLT Phototherapeutics Inc, Seattle, WA, 1999.
172. Ulrich B, Frey FJ, Speck RF, Frey BM. Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction. J Pharmacol Exp Ther. 1992; 260: 487-90.
173. McAllister WAC, Thompson PJ, Al-Habel SM, Rogers HJ. Rifampicin reduced effectiveness and bioavailability of prednisolone. Br Med J 1983; 286: 923-25.
174. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM Jr, Lemann J Jr. Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA 1976; 236: 1958-60.
175. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial trauma. N Engl J Med 1972; 286: 1125-28.
176. Gambertoglio J, Holford N, Kapusnik JE, Nisikawa R, Saltiel M, Stanik-Lizak P, et al. Enhancement of prednisolone elimination by anticonvulsants in renal transplant recipients. Clin Pharmacol Ther 1982; 31: 228.
177. Product Information. Matulane®, procarbazine, Roche Laboratories, Nutley, NJ, 1998.
178. Brown CS, Bryant SG. Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharm 1988; 22: 232-35.
179. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13.
180. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997; 62: 225-29.
181. Koranyi L, Gero L. Influence of diphenylhydantoin on the effect of streptozotocin (letter). Br Med J 1979; 1: 127.
182. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. Br Med J 1989; 298: 93-94.
183. Lodwick R, McConkey B, Brown AM. Life Threatening interaction between tamoxifen and warfarin. Br Med J 1987; 295: 1141.
184. Richie LD, Grant SM. Tamoxifen-warfarin interactions: the Aberdeen hospitals drug file. Br Med J 1989; 298: 1253.
185. Kivisto KT, Villikka K, Nyman L, Antilla M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998; 64: 648-54.
186. Baker DK, Relling MV, Pui C-H, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-15.
187. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF. Phenytoin alters the disposition of topotecan and N-desmethyl metabolism in a patient with medulloblastoma. Clin Cancer Res 1998; 4: 783-89.
188. Product information. Fareston®, toremifene. Schering Corp, NJ, 1999.
189. Fex G, Larsson K, Andersson A, Berggren-Soderlund M. Low serum concentration of all-trans and 13-cis retinoic acids in patients treated with phenytoin, carbazepaine and valproate. Possible relation to teratogenicity. Arch Toxicol 1995; 69: 572-74.
190. Heusner JJ, Franklin MR. Inhibition of metabolism of the 'nonclassical' antifolate, trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline) by drugs containing an imidazole moiety. Pharmacology 1985; 30: 266-72.
191. Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E. Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995; 35: 188-90.
192. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18: 1304-307.
193. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induces neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71: 311-12.
194. Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998; 20: 123-24.
195. Weber DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. Lancet. 1993; 341: 558-59.
196. Bertrand Y, Capdevile R, Balduck N, Phillippe N. Cyclosporine. A used to reverse drug resistance increases vincristine neurotoxicity. Am J Hematol 1992; 40: 158-59.
197. Villikka K, Kivisto KT, Maenpaa H, Joensuu H. Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999; 66: 589-93.
198. Fedeli L. Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989; 64: 1805-11.
199. Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996; 14: 935-40.
200. Bosque E. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. Ann Intern Med 2001; 134: 427.
201. May S. Significant drug-drug interactions in the oncology patient. Semin Oncol 1992; 8: 95-101.
202. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokin 1989; 16: 327-36.
203. Canellos GP, Haskell CM, Arseneau J, Carbone PP. Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man - a preliminary report. Cancer Chemother Rep. 1969; 53: 67-69.
204. Ciummo PE, Katz NL. Interactions and drug-metabolizing enzymes. Am Pharm 1995; 35/9: 41-51.
205. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug information handbook, ninth edition. Hudson, OH: American Pharmaceutical Association, 2001-2002.
206. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-30.
207. Goldwasser F, Lemoine A, Gross M. Topotecan is a cytochrome P450-3A inhibitor: clinical and pharmacologic evidence. Proc Am Assoc Cancer Res 1999; 40: 84.
208. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992; 261: 491-96.
209. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced Cyclophsophamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57: 1946-54.
210. Murray M, Butler AM, Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6-beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol Exp Ther 1994; 270: 645-49.
211. Granvil CP, Madan A, Sharkawi M, Parkinson A. Wainer IW. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of ®- and (S)-ifosfamide in human liver microsomes. Drug Metab Disp 1999; 27: 533-41
212. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by aromatase. Drug Metab Dispos. 1997; 25: 598-602.
213. Rahman A, Korzekwa KR, Grogan J, Gonzalez J. Harris JW. Selective biotransformation of taxol to 6-alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-46.
214. Kumar KN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6-alpha-hydroxylation. J Pharmacol Exp Ther 1994; 268: 1160-65.
215. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as\ the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911-19.
216. Product Information. Gleevec®, imatinib mesylate. Novartis Pharmaceuticals Corp. (PI revised 05/2001).
217. McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-transretinoic acid 4-hydroxylation. Biochem Pharmacol. 2000; 60: 517-26.
218. Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol. 1999; 58: 1201-208.
219. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53: 5121-26. 1985; 66: 1733-41.
220. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002; 72: 265-75.
221. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886-93.
222. Facts and Comparisons Staff, eds. Drug interaction facts 2002. St. Louis, MO: Fact and Comparisons, 2001.
223. Kintzel PE, Dorr RT. Antitumor treatment-anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21: 33-64.
224. Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high dose methotrexate. Cancer Treat Rep 1982; 66: 1733-41
225. Bleyer A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51.
226. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother Pharmacol 1988; 21: 163-67.
227. Ballet F, Vrignaud P, Robert J, Rey C, Poupon R. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol. 1987; 19: 240-45.
228. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
229. Jackson DV Jr, Castle MC, Bender RA. Biliary excretion of vincristine. Clin Pharmacol Ther. 1978; 24: 101-107.
230. Aronoff GR, Berns JS, Brier ME. Drug prescribing in renal failure. Dosing guidelines for adults, fourth edition. Philadelphia, PA: American College of Physicians, 1999.
231. Patterson WP, Reams GP. Renal and electrolyte abnormalities due to chemotherapy. In Perry MC ed. The chemotherapy sourcebook, third edition. Philadelphia: Lippinott Willimas & Wilkins, 2001; 494-504.
232. Joel S, Clark P, Slevin M. Renal function and etoposide pharmacokinetics: is dose modification necessary? Proc Am Soc Clin Oncol 1991; 10: 103.
233. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-76.
234. Mustafa Samur. Docetaxel and liver dysfunction: is it absolutely contraindicated? Am J Clin Oncol 2001; 24: 319-21.
235. Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetics and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34: S76-83.
236. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15: 833-39.
237. Galkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ. An extended phase II trial in ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10: 337-43.
238. Baker SD, Ravdin P, Aylesworth C, Smetzer L, Bruno R, Vernillet L, et al. A phase I and pharmacokinetic (PK) study of docetaxel in cancer patients (PTS) with liver dysfunction due to malignancies. Proc Am Soc Clin Oncol 1998; 17: 192.
239. Zamboni WC, Heideman RL, Meyer WH, Gajjar AJ, Crom WR, Stewart CF. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function. Proc Am Soc Clin Oncol 1996; 15: 180.
240. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996; 88: 817-24.
241. Trissel LA. Handbook on injectable drugs. eleventh edition. Bethesda, MD: American Society of Health-System Pharmacists, 2001.
242. Crom WR, Evans WE. Methotrexate. In Evans WE, Schentag JJ, Jusko WJ, eds. Appliedd pharmacokinetics. Principles of therapautics drug monitoring, third edition. Vancouver, WA: Applied Therapautics. Inc., 1992, chapter 29.
243. Ackland SP, Schilsky RL. High-dose methotrexate: A critical reappraisal. J Clin Oncol 1987; 5: 2017-31.
244. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-29.
245. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dos and excretion pattern. Eur J Cancer 1972; 8: 409-14.
246. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentration and toxicity. J Clin Oncol 1994; 12: 1667-72.
247. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphovytic leukemia. N Engl J Med 1986; 314: 471-77.
248. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630-34.
249. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy base on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.
250. Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney E, Frei E III. High dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 1977; 50: 1039-47.
251. Nixon PF, Bertino JR. Effective absorption and utilization of oral formyltetrahydrofolate in man. N Engl J Med 1972; 286: 175-79.
252. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15: 489-94.
253. Fei E III, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980; 68: 370-76.
254. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-31.
255. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
256. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984; 53: 2046-52.
257. Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 1998; 79: 23-27.
258. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-89.
259. Rajan R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995; 13: 42-46.
260. Package insert. Coumadin (warfarin sodium). Wilmington, Delaware: DuPont Pharma. June, 1996.
261. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83.
262. Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol. 2002; 20: 33-41.
263. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-68.
264. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-94.